STAT

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

Time for an annual tradition: the best biopharma CEOs of 2018. Vote for your favorite!

It’s been a roller-coaster year in biopharma. The Food and Drug Administration set a new record for drug approvals, and investors bought a record number of biotech initial public offerings. But the performance of those IPOs has been mixed and the most closely followed biotech stock index is negative for the year. For all the volatility on the business side of biotech, the industry’s ability to translate science into new medicines marches on — for now.

The end of the year also offers an opportunity: To determine the best biopharma CEO of, this process is about more than just whimsy. I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted others while coming up with a list of finalists. A few worthy candidates didn’t make the cut.

You're reading a preview, sign up to read more.

More from STAT

STAT2 min read
Purdue Pharma, Maker Of OxyContin And Other Drugs, Files For Bankruptcy
Facing thousands of lawsuits alleging that it helped spark the opioid addiction crisis, privately held Purdue Pharma announced it had filed for bankruptcy,
STAT3 min readSociety
Opinion: A Dangerous View: Why It’s A Mistake For Medical Schools To Ignore Social Justice
An op-ed in the Wall Street Journal called for getting back to basics in medical school and forgoing teaching on gun violence or other social issues. The author has it…
STAT7 min read
Could Editing The DNA Of Embryos With CRISPR Help Save People Who Are Already Alive?
There is a little-discussed potential application of CRISPR: tweaking its DNA of embryos to help save someone who is already alive.